Bettencourt Andreia, Boleixa Daniela, Guimarães Ana Luísa, Leal Bárbara, Carvalho Cláudia, Brás Sandra, Samões Raquel, Santos Ernestina, Costa Paulo Pinho, Silva Berta, da Silva Ana Martins
Immunogenetics Laboratory, Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto (UP), Porto, Portugal; Unit for Multidisciplinary Research in Biomedicine (UMIB), Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto (UP), Porto, Portugal.
Immunogenetics Laboratory, Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto (UP), Porto, Portugal.
J Neuroimmunol. 2017 Aug 15;309:34-37. doi: 10.1016/j.jneuroim.2017.05.005. Epub 2017 May 11.
The cause of Multiple Sclerosis (MS) remains poorly understood, but it is widely believed to be an autoimmune disease occurring in genetically susceptible individuals after exposure to as-yet undefined environmental factors. One of these environmental factors is vitamin D, a well-known immune modulator. The biologically active form of vitamin D, 1,25-dihydroxyvitamin D3, has been shown to exert its immune modulatory properties through its nuclear receptor (VDR) namely by inhibiting the proliferation of Th cells. The purpose of this study was to evaluate the influence of FokI VDR polymorphism in MS development and progression.
A group of 533 unrelated Portuguese patients with a definitive diagnosis of MS and 446 ethnically matched healthy controls were included in the study. FokI was genotyped using a PCR-based TaqMan Genotyping Assay and serum 25-hydroxyvitamin D [25(OH)D] was also assessed.
A statistically significant higher frequency of the ff genotype was observed in MS patients (15.6% vs. 10.1%, p=0.012, OR (95% CI)=1.687(1.120-2.541)). No differences were observed in the frequencies of the FokI polymorphism according to disease course or with progression of disability. None of the genotypes was significantly associated with 25(OH)D serum levels.
An association between FokI ff genotype and MS susceptibility was found, but not with disease form or progression. Additional clinical and experimental studies should take the FokI VDR polymorphism into account, and further clarify the role of vitamin D, its metabolites and its receptor in MS.
多发性硬化症(MS)的病因仍未完全明确,但普遍认为它是一种自身免疫性疾病,发生在具有遗传易感性的个体中,这些个体在接触尚未明确的环境因素后发病。其中一个环境因素是维生素D,它是一种众所周知的免疫调节剂。维生素D的生物活性形式1,25-二羟基维生素D3已被证明通过其核受体(VDR)发挥免疫调节特性,即通过抑制Th细胞的增殖。本研究的目的是评估FokI VDR基因多态性对MS发生和发展的影响。
本研究纳入了一组533名确诊为MS的无亲缘关系的葡萄牙患者以及446名种族匹配的健康对照。使用基于PCR的TaqMan基因分型检测法对FokI进行基因分型,并评估血清25-羟基维生素D[25(OH)D]水平。
在MS患者中观察到ff基因型的频率在统计学上显著更高(15.6%对10.1%,p = 0.012,OR(95%CI)=1.687(1.120 - 2.541))。根据病程或残疾进展情况,FokI基因多态性的频率没有差异。没有一种基因型与25(OH)D血清水平显著相关。
发现FokI ff基因型与MS易感性之间存在关联,但与疾病形式或进展无关。更多的临床和实验研究应考虑FokI VDR基因多态性,并进一步阐明维生素D及其代谢产物和受体在MS中的作用。